Open AccessUrotensin II levels in patients with inflammatory bowel disease
Author(s) -
Damir Aličić,
Dinko Martinović,
Doris Rušić,
Piero Marin Živković,
Ivana Tadin Hadjina,
Marino Vilović,
Marko Kumrić,
Daria Tokic,
Daniela ŠupeDomić,
Slaven Lupi-Ferandin,
Joško Božić
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i36.6142
Subject(s) - inflammatory bowel disease , medicine , gastroenterology , crohn's disease , ulcerative colitis , disease , immunology
Patients with inflammatory bowel disease (IBD) are associated with increased cardiovascular risk and have increased overall cardiovascular burden. On the other hand, urotensin II (UII) is one of the most potent vascular constrictors with immunomodulatory effect that is connected with a number of different cardiometabolic disorders as well. Furthermore, patients with ulcerative colitis have shown increased expression of urotensin II receptor in comparison to healthy controls. Since the features of IBD includes chronic inflammation and endothelial dysfunction as well, it is plausible to assume that there is connection between increased cardiac risk in IBD and UII.